Susquehanna International Group’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-100,853
| Closed | -$54K | – | 13814 |
|
|
2024
Q4 | $54K | Buy |
100,853
+26,974
| +37% | +$18.8K | ﹤0.01% | 11643 |
|
|
2024
Q3 | $130K | Sell |
73,879
-427,918
| -85% | -$597K | ﹤0.01% | 10869 |
|
|
2024
Q2 | $587K | Buy |
501,797
+397,907
| +383% | +$996K | ﹤0.01% | 7876 |
|
|
2024
Q1 | $939K | Sell |
103,890
-40,014
| -28% | -$389K | ﹤0.01% | 7070 |
|
|
2023
Q4 | $1.56M | Buy |
143,904
+10,814
| +8% | +$81K | ﹤0.01% | 5896 |
|
|
2023
Q3 | $1.07M | Buy |
133,090
+67,573
| +103% | +$562K | ﹤0.01% | 6479 |
|
|
2023
Q2 | $712K | Sell |
65,517
-287,688
| -81% | -$2.46M | ﹤0.01% | 7483 |
|
|
2023
Q1 | $2.44M | Sell |
353,205
-13,360
| -4% | -$83.8K | ﹤0.01% | 4741 |
|
|
2022
Q4 | $1.46M | Buy |
366,565
+329,660
| +893% | +$1.62M | ﹤0.01% | 5347 |
|
|
2022
Q3 | $245K | Buy |
36,905
+10,139
| +38% | +$62.4K | ﹤0.01% | 10320 |
|
|
2022
Q2 | $130K | Sell |
26,766
-4,832
| -15% | -$29.4K | ﹤0.01% | 11208 |
|
|
2022
Q1 | $295K | Sell |
31,598
-42,086
| -57% | -$418K | ﹤0.01% | 10318 |
|
|
2021
Q4 | $875K | Sell |
73,684
-5,149
| -7% | -$59.5K | ﹤0.01% | 7641 |
|
|
2021
Q3 | $897K | Buy |
78,833
+49,880
| +172% | +$686K | ﹤0.01% | 7851 |
|
|
2021
Q2 | $519K | Sell |
28,953
-232,432
| -89% | -$3.74M | ﹤0.01% | 9491 |
|
|
2021
Q1 | $4.05M | Buy |
261,385
+41,439
| +19% | +$599K | ﹤0.01% | 4337 |
|
|
2020
Q4 | $2.68M | Buy |
219,946
+118,949
| +118% | +$1.66M | ﹤0.01% | 4506 |
|
|
2020
Q3 | $1.3M | Buy |
100,997
+19,127
| +23% | +$165K | ﹤0.01% | 5500 |
|
|
2020
Q2 | $832K | Sell |
81,870
-33,580
| -29% | -$309K | ﹤0.01% | 6300 |
|
|
2020
Q1 | $937K | Buy |
115,450
+1,689
| +1% | +$14.6K | ﹤0.01% | 5559 |
|
|
2019
Q4 | $983K | Buy |
113,761
+46,305
| +69% | +$260K | ﹤0.01% | 5564 |
|
|
2019
Q3 | $416K | Sell |
67,456
-21,581
| -24% | -$174K | ﹤0.01% | 7675 |
|
|
2019
Q2 | $1.48M | Buy |
89,037
+59,532
| +202% | +$1.03M | ﹤0.01% | 4807 |
|
|
2019
Q1 | $493K | Buy |
+29,505
| New | +$425K | ﹤0.01% | 6312 |
|
|
2018
Q2 | – | Sell |
-101,548
| Closed | -$2.25M | – | 10618 |
|
|
2018
Q1 | $1.55M | Buy |
101,548
+84,507
| +496% | +$2.01M | ﹤0.01% | 4391 |
|
|
2017
Q4 | $556K | Sell |
17,041
-4,364
| -20% | -$118K | ﹤0.01% | 6439 |
|
|
2017
Q3 | $503K | Buy |
+21,405
| New | +$240K | ﹤0.01% | 6494 |
|
|
2016
Q4 | – | Sell |
-14,442
| Closed | -$105K | – | 10305 |
|
|
2016
Q3 | $105K | Buy |
+14,442
| New | +$97.6K | ﹤0.01% | 7918 |
|
Susquehanna International Group's MRNS Position: Q1 2025 in Review
Susquehanna International Group sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2025, closing a stake of 100,853 shares — an estimated $54K sold.
Susquehanna International Group first reported a position in MRNS in Q3 2016 and held it in 28 quarters. The position peaked at $4.05M in Q1 2021. 0 funds tracked by Wall St. Rank hold MRNS as of Q1 2025.
- Susquehanna International Group reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2025 after selling out during the quarter.
- Susquehanna International Group sold 100,853 Marinus Pharmaceuticals, Inc shares in Q1 2025, an estimated $54K.
- Susquehanna International Group first reported a position in Marinus Pharmaceuticals, Inc in Q3 2016 and held it in 28 quarters.
- Susquehanna International Group's Marinus Pharmaceuticals, Inc position peaked at $4.05M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2025.
Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.